R&D channel feed – Endpoints News

R&D channel feed

Bristol Myers' Opdivo-Yervoy beats Lenvima and Nexavar in Phase 3 early liver cancer trial

11 months ago

BridgeBio spotlights 12 and 18-month data for potential achondroplasia drug in children

11 months ago

Annexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré syndrome

11 months ago

Sanofi touts Phase 3 Sarclisa data in multiple myeloma as it plays catch-up with J&J’s Darzalex

11 months ago

At ASCO: big readouts, revenue questions, and the ups and downs of ADCs

11 months ago

Structure's oral GLP-1 produces comparable weight loss to Lilly's oral candidate

11 months ago

After Phase 3 win, Arrowhead's RNAi chases Ionis to market entry in rare genetic disorder

11 months ago

Takeda outlines mid-stage narcolepsy data that prompted 'rapid' move into Phase 3

11 months ago

Caribou says partial HLA matching will improve durability of response to cell therapy

11 months ago

Exclusive: Isotope shortage forces pause of Bristol Myers Phase 3 radiopharmaceutical trial

11 months ago

A small group of melanoma patients may need far less immunotherapy with surgery, study suggests

11 months ago

Updated: With a promising new Keytruda contender, Summit prepares to spar with Merck

11 months ago

Daiichi Sankyo, AstraZeneca say Enhertu works better than chemo in certain breast cancer patients

11 months ago

AstraZeneca, J&J share new data in bids to expand reach of lung cancer drugs

11 months ago

GSK plots Blenrep’s return with more data on its ADC for multiple myeloma

11 months ago

Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%

11 months ago

GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer

11 months ago

BMS details confirmatory trial win for KRAS inhibitor Krazati

11 months ago

Iovance's TIL therapy plus Keytruda show durable treatment effect in melanoma, but access remains a question

11 months ago

Immunocore unveils early-stage data of skin cancer treatment that led it to start Phase 3 trial

11 months ago

'Invisible hand' of inherited genetics can drive cancer risk, new study suggests

11 months ago

#ASCO24: Novartis' new CML treatment tops older drugs, including Gleevec, in Phase 3 trial

11 months ago

#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study

11 months ago

Ionis outlines Phase 3 data for rare disease drug, preps for another potential launch

11 months ago

First page Previous page 39 40 414243 44 45 Next page Last page